(firstQuint)Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis.

 This study will evaluate how oral treprostinil can affect pulmonary vascular resistance, as assessed by right heart catheterization, and exercise capacity, as assessed by the Six-Minute Walk Test.

 This is a 16-week study that will involve at least 10 clinical trial centers.

 The expected enrollment period is around 24 months and 52 subjects will be entered into the study.

.

 Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis@highlight

This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.

